South Korea: Pharmaceutical Industry Infrastructure Overview

Datamonitor, July 2011, Pages: 42

Introduction

South Korea is among the top 10 new drug developers in the world. It has high quality standards and a skilled workforce, plus cost benefits, making it an attractive clinical trials destination. Furthermore, with experience in manufacturing biologics, South Korea is set to become a global leader in the development of biosimilars.

Features and benefits

- Understand drivers and resistors for accessing the South Korean pharmaceutical market.
- Analyze ongoing trends in the R&D and manufacturing sector in South Korea.
- Examine the leading pharmaceutical companies in South Korea, their infrastructure and current strategy in this market.

Highlights

With significant government support and investment, particularly in the biotechnology sector, increased foreign investment from multinational companies is expected. South Korea is more innovative than its emerging Asian neighbors, and offers the same cost benefits and rapid recruitment, making it an attractive clinical trials destination.
With experience in manufacturing biologics, South Korea is set to become a global leader in the development of biosimilars. Already a number of significant deals have been struck between multinational and domestic companies to produce a range of blockbuster biosimilar candidates.
While many of the top-selling pharmaceuticals in South Korea are marketed by large multinationals, there are some sizable Korean drug makers with novel drugs of their own, and the leading companies by sales revenue include a mix of both domestic and multinational firms.

Your key questions answered

- What are the government subsidies to facilitate investments in the South Korean pharmaceutical market?
- Which are the top 10 pharmaceutical companies, and how have they expanded their business operations?

Executive Summary
South Korea – Introduction
South Korea – Strategic scoping and focus
South Korea – Key findings
Pharmaceutical industry infrastructure
Related reports
Upcoming related reports
SOUTH KOREA – PHARMACEUTICAL INDUSTRY INFRASTRUCTURE ANALYSIS
South Korea – Pharmaceutical industry metrics
South Korea – R&D infrastructure trends
Korean research organizations have significant in-house capabilities and capacity
Multinational companies have set up R&D centers in Korea
The government has introduced policies to stimulate domestic R&D
South Korea is expected to be a leader in biosimilars development
South Korea – Manufacturing infrastructure trends
There are a large number of generics and API manufacturers in South Korea
Experience with biologics and gene and cell therapies is expanding
South Korea – Outsourcing trends
Contract research services benefit from public-private partnerships
South Korea faces stiff competition from nearby Asian rivals in the outsourcing sector
South Korea – Distribution trends
Domestic distribution is primarily through pharmacies in South Korea
An abundance of pharmaceutical wholesalers has led to fragmented distribution networks
Over-the-counter drugs are confined to pharmacy sale
SOUTH KOREA – KEY COMPANY INFRASTRUCTURE
South Korea – Leading domestic pharmaceutical companies
Dong-A Pharmaceuticals
Green Cross Corporation
Yuhan Corporation
Hanmi Pharmaceuticals
Daewoong Pharmaceutical Co.
LG Life Sciences
JW Pharmaceuticals
South Korea – Leading multinational pharmaceutical companies
GlaxoSmithKline
Novartis
Pfizer
Sanofi
Merck Sharp & Dohme (Merck & Co.)
BIBLIOGRAPHY
Publications and online articles
Datamonitor reports and products
APPENDIX
Exchange rates used in this report

Customers who bought this item also bought

• Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth
• Biosimilar Opportunities: Pipelines and Companies
• South Korea: Generics and Biosimilars Overview
• Taking Advantage of Protein-Based Therapy Opportunities
• PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2012/2013
• Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways in the US to Spur Market Growth
• Biosimilars - Global Strategic Business Report
• Analysis of European Biosimilars Market
• The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways
• Biotechnology in India - Global Business Strategic Report